Search

Hironao M Wakabayashi

from Rochester, NY
Age ~62
Get Report
Also known as:
Hir Wakabayashi
Phone and address:
66 Northumberland Rd, Rochester, NY 14618
(585) 461-1068
Related to:
Mihoko Wakabayashi, 60Aoi Wakabayashi, 33Nadia Wakabayashi, 29Luke Wakabayashi, 28Shin Wakabayashi, 36
Connected to:
Aki Wakabayashi, 48Akihito A Wakabayashi, 65Rena Wakabayashi, 37Reyn T Wakabayashi, 37Taichi Wakabayashi, 66Yoshi Wakabayashi, 66Gourang A Wakade, 44Shilpa V Wakade, 44Vikram S Wakade, 35Goji Wakamatsu, 43

Hironao Wakabayashi Phones & Addresses

  • 66 Northumberland Rd, Rochester, NY 14618 (585) 461-1068
  • 136 Greystone Ln, Rochester, NY 14618 (585) 461-1068 (716) 461-1068
  • Irvine, CA
  • Delevan, NY
  • Sugar Land, TX
  • Houston, TX

Work

Company: University of rochester, department of biochemistry and biophysics Nov 1997 Position: Research assistant professor

Education

School / High School: Fukushima Medical University- Fukushima, Japan 1988 Specialities: PhD in Pathology

Skills

Protein engineering (extensive hands-on ...

Emails

h***[email protected]

Resumes

Resumes

Hironao Wakabayashi Photo 1

Hironao Wakabayashi Rochester, NY

View page
Work:
University of Rochester, Department of Biochemistry and Biophysics

Nov 1997 to 2000
Research Assistant Professor
The Institute for Molecular Medicine
Huntington Beach, CA
Sep 1996 to Oct 1997
Research Assistant Professor
University of Texas, MD Anderson Cancer Center
Houston, TX
Apr 1992 to Aug 1996
Postdoctoral Fellow
Education:
Fukushima Medical University
Fukushima, Japan
1988 to 1992
PhD in Pathology
Fukushima Medical University
Fukushima, Japan
1982 to 1988
Professional in Medicine
Skills:
Protein engineering (extensive hands-on experientce of site-directed mutagensis)

Publications

Us Patents

Recombinant Factor Viii Having Reduced Inactivation By Activated Protein C

View page
US Patent:
8183345, May 22, 2012
Filed:
Jul 25, 2008
Appl. No.:
12/179951
Inventors:
Philip J. Fay - Pittsford NY, US
Hironao Wakabayashi - Rochester NY, US
Fatbardha Varfaj - San Francisco CA, US
Assignee:
University of Rochester - Rochester NY
International Classification:
A61K 38/37
C07K 14/755
US Classification:
530383, 514 141
Abstract:
The present invention relates to a recombinant factor VIII that is characterized by one or more mutations within a region surrounding an activated protein C cleavage site, which one or more mutations result in a reduced rate of inactivation by activated protein C. Isolated nucleic acid molecules, recombinant expression vectors, and host cells suitable for expression of the recombinant factor VIII are also disclosed. The recombinant factor VIII can be used for the treatment of clotting disorders, such as hemophilia A.

Recombinant Factor Viii Having Increased Stability

View page
US Patent:
8338571, Dec 25, 2012
Filed:
Jul 25, 2008
Appl. No.:
12/179801
Inventors:
Philip J. Fay - Pittsford NY, US
Hironao Wakabayashi - Rochester NY, US
Assignee:
University of Rochester - Rochester NY
International Classification:
A61K 38/37
C07K 14/755
US Classification:
530383, 514 141
Abstract:
The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.

Recombinant Factor Viii Having Enhanced Stability Following Mutation At The A1-C2 Domain Interface

View page
US Patent:
8637448, Jan 28, 2014
Filed:
Sep 13, 2011
Appl. No.:
13/231948
Inventors:
Philip J. Fay - Pittsford NY, US
Hironao Wakabayashi - Rochester NY, US
Assignee:
University of Rochester - Rochester NY
International Classification:
A61K 38/37
C07K 14/755
US Classification:
514 11, 514 135, 514 137, 514 141
Abstract:
The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.

Recombinant Factor Viii Having Increased Specific Activity

View page
US Patent:
20070265199, Nov 15, 2007
Filed:
Dec 2, 2004
Appl. No.:
10/581471
Inventors:
Philip Fay - Pittsford NY, US
Hironao Wakabayashi - Rochester NY, US
International Classification:
A61K 38/37
A61P 7/00
C07H 21/04
C07K 14/755
C12N 15/00
C12N 5/00
C12P 21/02
US Classification:
514012000, 435320100, 435325000, 435069600, 530383000, 536023400
Abstract:
The present invention relates to recombinant factor VIII having a specific activity that is higher than that of the corresponding wild-type factor VIII. The present invention also relates to methods of making and using the recombinant factor VIII. The present invention also relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.

Recombinant Factor Viii Having Increased Stability

View page
US Patent:
20130085110, Apr 4, 2013
Filed:
Nov 30, 2012
Appl. No.:
13/691474
Inventors:
University of Rochester - Rochester NY, US
Hironao Wakabayashi - Rochester NY, US
Assignee:
UNIVERSITY OF ROCHESTER - Rochester NY
International Classification:
C07K 14/755
US Classification:
514 141, 530383, 536 235, 4353201, 435325, 4352523, 435348, 43525411, 4352542, 435419, 4352572, 435 696
Abstract:
The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.

Recombinant Factor Viii Having Increased Stability

View page
US Patent:
20140056861, Feb 27, 2014
Filed:
Oct 11, 2013
Appl. No.:
14/052452
Inventors:
Hironao Wakabayashi - Rochester NY, US
Assignee:
University of Rochester - Rochester NY
International Classification:
C12N 15/86
A61K 35/12
US Classification:
424 9321, 536 235, 4353201, 435325, 514 44 R
Abstract:
The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.

Recombinant Factor Viii Having Enhanced Stability Following Mutation At The A1-C2 Domain Interface

View page
US Patent:
20150037301, Feb 5, 2015
Filed:
Oct 19, 2014
Appl. No.:
14/517883
Inventors:
Philip J. Fay - Pittsford NY, US
Hironao Wakabayashi - Rochester NY, US
Assignee:
UNIVERSITY OF ROCHESTER - Rochester NY
International Classification:
C07K 14/755
A61K 38/37
US Classification:
424 9321, 530383, 514 141, 536 235, 4353201, 435352, 43525233, 435348, 43525411, 4352542, 43525421, 435419, 435414, 4352572
Abstract:
The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.

Recombinant Factor Viii Having Enhanced Stability Following Mutation At The A1-C2 Domain Interface

View page
US Patent:
20140120071, May 1, 2014
Filed:
Dec 27, 2013
Appl. No.:
14/141983
Inventors:
Philip J. FAY - Pittsford NY, US
Hironao WAKABAYASHI - Rochester NY, US
Assignee:
UNIVERSITY OF ROCHESTER - Rochester NY
International Classification:
C07K 14/755
US Classification:
424 9321, 536 235, 4353201, 435325, 514 44 R
Abstract:
The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
Control profile
Hironao M Wakabayashi from Rochester, NY, age ~62 Get Report